Silencing CD24 Inhibits Proliferation, Migration, and Chemoresistance in Triple-Negative Breast Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• CD24 is significantly overexpressed in triple-negative breast cancer (TNBC) compared to other breast cancer subtypes and normal tissue.
• CD24 overexpression correlates with increased tumorigenesis, metastasis, and drug resistance in TNBC.
• CD24 acts as a "don't eat me" signal, inhibiting macrophage-mediated phagocytosis of cancer cells.

Purpose of the Study:

• To investigate the therapeutic potential of downregulating CD24 in TNBC.
• To evaluate the efficacy of CD24-targeting siRNAs in TNBC cells.

Main Methods:

• Design and evaluation of four CD24 siRNAs for silencing efficiency and biological activity in TNBC cells.
• Assessment of CD24 silencing impact on doxorubicin resistance.
• Examination of CD24 silencing effects on macrophage-mediated phagocytosis of TNBC cells.

Main Results:

• Identification of a potent CD24 siRNA that inhibits TNBC cell proliferation, migration, and invasion.
• CD24 silencing induced apoptosis and S-phase cell cycle arrest in TNBC cells.
• Silencing CD24 increased TNBC cell sensitivity to doxorubicin and enhanced macrophage-mediated phagocytosis.

Conclusions:

• CD24-targeting siRNA represents a promising therapeutic strategy for TNBC.
• This approach may also be beneficial for other cancers with CD24 overexpression.